Scholar Rock
620 Memorial Drive, 2nd Floor
Cambridge
Massachusetts
02139
United States
Tel: 857-259-3860
Fax: 866-493-4935
Website: http://www.scholarrock.com/
100 articles with Scholar Rock
-
Scholar Rock Reports Second Quarter 2022 Financial Results and Highlights Business Progress
8/8/2022
Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported financial results and corporate updates for the second quarter ended June 30, 2022.
-
Scholar Rock Announces the Addition of Srinivas Akkaraju, M.D., Ph.D. to Its Board of Directors
7/26/2022
Scholar Rock announced that Dr. Srinivas Akkaraju, Founder and Managing General Partner at Samsara BioCapital, has been appointed to Scholar Rock’s Board of Directors as an independent director.
-
Scholar Rock to Participate in the 2022 Wedbush PacGrow Healthcare Conference
7/19/2022
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the “Muscle Beach” panel for the 2022 Wedbush PacGrow Healthcare Conference, being held virtually on August 9, 2022, at 2:20 pm ET.
-
Scholar Rock to Present New Preclinical Data on its Targeted Approach to the LTBP-TGFβ1 Complex for Anti-Fibrotic Therapy at the 2022 FASEB Science Research Conference
7/15/2022
Scholar Rock today announced the company will present new data that highlight the development of its highly selective, context-dependent TGFβ1 antibody.
-
Scholar Rock to Present Phase 3 SAPPHIRE Trial Design at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)
7/1/2022
Scholar Rock (NASDAQ: SRRK), today announced an e-poster presentation by Thomas Crawford, M.D., on the design of the company’s ongoing SAPPHIRE Phase 3 clinical trial in spinal muscular atrophy (SMA) at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) in Brussels, Belgium (July 5 – 9, 2022).
-
Funding for life sciences companies picked up this week as investors pumped new money into firms developing treatments for spinal muscular atrophy (SMA), immuno-oncology, allergies and rare diseases.
-
Extension data from the Phase II TOPAZ trial showed that apitegromab yielded sustained and continued benefits in non-ambulatory patients with types 2 and 3 spinal muscular atrophy (SMA).
-
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
6/17/2022
Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24-months of treatment.
-
Scholar Rock Announces $205 Million Registered Direct Offering
6/17/2022
Scholar Rock today announced that it has entered into a securities purchase agreement with certain institutional investors to sell, in a registered direct offering, 16,326,530 shares of common stock.
-
Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference
6/9/2022
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company will deliver two podium presentations on 24-month data from the TOPAZ Phase 2 clinical trial at the 2022 SMA Research and Clinical Care meeting.
-
Scholar Rock to Present at Jefferies Global Healthcare Conference 2022
6/2/2022
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 8:00 a.m. ET.
-
As Scholar Rock prepares to move forward with its experimental assets for spinal muscular atrophy, it has terminated 25% of its staff and also announced the loss of its chief medical officer.
-
Scholar Rock Reports First Quarter 2022 Financial Results and Updates Strategic Priorities
5/16/2022
Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, provided a business update and reported financial results for the first quarter ended March 31, 2022.
-
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the 2022 European Paediatric Neurology Society Congress
4/21/2022
Scholar Rock today announced that it is delivering a podium presentation at the 14th European Paediatric Neurology Society (EPNS) Congress, taking place in Glasgow, UK from April 28 - May 2, 2022.
-
Scholar Rock Presents Data Analysis of Multiple Efficacy Endpoints from the Apitegromab TOPAZ Phase 2 Trial at the American Academy of Neurology 2022 Annual Meeting
3/22/2022
Scholar Rock today announced that it is presenting encore data in an e-poster at the American Academy of Neurology (AAN) 2022 Annual Meeting, taking place in Seattle, Washington (April 2-7) and virtually (April 24-26).
-
Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
3/13/2022
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that it will present a poster at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference.
-
Scholar Rock Reports Full Year 2021 Financial Results and Highlights Business Progress
3/7/2022
Scholar Rock today reported financial results for the full year ended December 31, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.
-
Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference
2/25/2022
Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference.
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
1/10/2022
Scholar Rock today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2022.
-
Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Scholar Rock today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 7:30 a.m. ET.